spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

Aridhia broadens European appeal with new RSRCH Health service in Netherlands

Aridhia

Aridhia, Vancis and MGRID announce the expansion of their partnership

Scottish clinical and translational informatics company Aridhia, Netherlands-based ICT service provider Vancis, and clinical datasets experts MGRID are today announcing the expansion of their existing partnership with the launch of a new research platform service, RSRCH-Health, into the Netherlands.

The initiative will be introduced at the Health-RI conference on December 1st in Amersfoort, Netherlands to an audience of researchers, academics and clinicians who are being encouraged to work together to enable ground-breaking biomedical research.

The growth of Aridhia’s operations outside the UK follows the partnership agreement with Vancis announced in mid-2015. A number of new jobs in both Scotland and the Netherlands are expected to be created as a result of this collaboration.

Based on Aridhia’s AnalytiXagility data analysis platform, RSRCH-Health was first established in early 2016 to deliver a digital research environment to Radboudumc Nijmegen in a three-year deal, making it the first University Medical Centre in the Netherlands to offer a digital platform to all research teams across the institution.

Radboudumc is currently rolling out RSRCH-Health across the entire organisation, providing analytical workspaces for up to 1600 research projects to accelerate the delivery of research studies into clinical practice.

The extended Vancis, Aridhia, and MGRID collaboration - which goes by the name RSRCH - signifies continued growth for Aridhia, one of Scotland’s data science success stories.

Chris Roche, Aridhia’s CEO, said of the new company: “The development of AnalytiXagility into a tailored offering for the Netherlands’ market is very exciting for Aridhia and is validation that our platform is precisely what research-driven organisations need to achieve the best outcomes.

“Research teams worldwide are realising the value in wide-scale collaboration around data, and together with Vancis and MGRID, we believe that RSRCH-Health represents an answer to the data challenges that they face.”

Eli Berkelmans, RSRCH Managing Director said: “RSRCH-Health gives us the means to deliver a unique on-demand, secure platform service specifically catering to the needs of researchers.

“It is already being used at Radboudumc by a number of showcase projects and thanks to word-of-mouth, it is generating interest across Europe. We’re excited about the opportunities this opens up to us and, more importantly, to research teams worldwide.”

The RSRCH-Health platform incorporates Aridhia’s existing AnalytiXagility services with infrastructure expertise from Vancis, and MGRID’s Aperture which speeds up creation of datasets for clinical research, to deliver a self-service capability which answers the specific requirements of the Netherland’s market.

Developed to deliver rapid change by enabling a multidisciplinary, collaborative approach to biomedical research, RSRCH-Health is available via the Amsterdam based RSRCH team and is suitable for individual studies, or as the digital environment for all projects within a research-driven institution.

This partnership adds to Aridhia’s growing portfolio of European projects as it exports AnalytiXagility to prominent research collaborations across the continent, including the ground-breaking European Prevention of Alzheimer’s Dementia (EPAD) project, an Innovative Medicines Initiative funded research programme.
phone 00 44 131 560 1470
web www.aridhia.com/
email Hobart House, 80 Hanover Street, Edinburgh, EH2 1EL
 
Print this page
Send to a friend
   
spacer
News and Press Releases

RWS Life Sciences Welcomes New VP of Quality

RWS Life Sciences welcomes Clarice Streets, ASQ, CMQ, OE, as Vice President, Global Quality and Process, in charge of the strategic direction and implementation of its Quality system, underlying organizational processes, and change management.
More info >>


White Papers

Orthogonal Approaches for the Analysis of Protein Sequence and Post Translational Modifications of a Monoclonal Antibody

RSSL

Monoclonal antibodies are an important class of biopharmaceuticals. They are expressed from living cells and therefore, are subject to complex biochemical pathways. Not all of these pathways are fully understood and many are known to be sensitive to subtle environmental changes during production. These changes may affect the final biopharmaceutical sequence, structure and post-translational modifications. This is in addition to any changes that may occur during subsequent purification. This means that the final product from one batch may be subtly different from another batch. Furthermore, each batch is a heterogeneous mix of similar molecules. Analysis of the degree of batch-tobatch variation, and batch heterogeneity, is therefore, very important to establish in order to be confident that the drug is safe and effective for medicinal use.
More info >>

Industry Events

SMi’s 9th Annual Biosimilars & Biobetters Conference

25-27 September 2018, Copthorne Tara Hotel, London, UK

Following the success of our previous events in both London and the US, Biosimilars and Biobetters UK 2018, SMi deliver a stellar speaker line-up and bring together a global audience of biosimilar experts to discuss the latest developments and future of the rapidly evolving and expanding biosimilars market.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement